Sammenlignet med placebo gav behandling med sitagliptin 100 mg signifikante forbedringer i HbA1c, i faste- plasma glucose (FPG) og i 2- timers postprandial glucose (2- timers PPG), når det blev sammenlignet med placebo i to undersøgelser, hvor den ene var af 18 ugers varighed og den anden af 24 ugers varighed..
Treatment with sitagliptin at 100 mg once daily as monotherapy provided significant improvements in HbA1c, fasting plasma glucose (FPG), and 2-hour post-prandial glucose (2-hour PPG), compared to placebo in two studies, one of 18- and one of 24-weeks duration.